MLIP
protein-codingmuscular LMNA interacting protein
Gene summary
Predicted to enable lamin binding activity and transcription corepressor activity. Predicted to be involved in negative regulation of cardiac muscle hypertrophy in response to stress; negative regulation of transcription by RNA polymerase II; and positive regulation of transcription by RNA polymerase II. Predicted to be located in PML body; nuclear envelope; and sarcolemma. Implicated in myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 1. [provided by Alliance of Genome Resources, Jun 2026]
- C6orf142
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~336.3 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0859322
Submitter: Ambry Genetics
Inheritance Pattern: AR
Disease ID:MONDO:0859322
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:0859322
Submitter: Labcorp Genetics (formerly Invitae)
Clinical Genomic Database (CGD)
Manifestation: Cardiovascular; Musculoskeletal
Intervention: Cardiovascular; Musculoskeletal
Rationale: The condition can involve cardiomyopathy and/or arrhythmia, and awareness may allow prompt diagnosis and mangement; Individuals may be at risk of rhabdomyolysis, and awareness may allow avoidance of precipitating factors, and prompt treatment of episodes
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to MLIP variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_001281747.2. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 7 | 1 | 8 | |||
| missense | 56 | 8 | 2 | 66 | ||
| nonsense | 5 | 5 | ||||
| start loss | 0 | |||||
| frameshift | 5 | 6 | 11 | |||
| splice donor/acceptor (+/-2bp) | 2 | 1 | 3 | |||
| Total | 10 | 8 | 57 | 15 | 3 | 93 |
Highest pathogenic variant AF is 0.0002092428
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_001268676.1 | 14 | MANE Select | |
| Ensembl | ENSP00000426290.1 | 14 | MANE Select | |
| RefSeq | NP_001268675.1 | 12 | Standard | |
| RefSeq | NP_612636.2 | 13 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Biological Process
- negative regulation of transcription by RNA polymerase II
- negative regulation of cardiac muscle hypertrophy
- positive regulation of transcription by RNA polymerase II
- negative regulation of cardiac muscle hypertrophy in response to stress
Cellular Component
- nucleus
- nuclear envelope
- PML body
- nuclear lumen
- sarcolemma
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000274897
- Coding exons
- 13
- Length
- 336299
- Individuals with no LoFs
- 125703
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 44
- Defined
- 125747
- p
- 0.000175
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | -0.710 | 266 | 235 | 1.13 | 0.0000114 | 2964 |
| Missense (PolyPhen) | 84 | 88.341 | 0.95086 | 1145 | ||
| Synonymous | -0.613 | 97 | 89.6 | 1.08 | 0.00000462 | 895 |
| Loss of Function | 0.0556 | 24 | 24.3 | 0.988 | 0.00000108 | 320 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00032 | 0.00031 | rare |
| Latino/Admixed American | 0.00029 | 0.00026 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.00011 | 0.00011 | rare |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0.00016 | 0.00016 | rare |
| South Asian | 0.00033 | 0.00033 | rare |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Required for precocious cardiac adaptation to stress through integrated regulation of the AKT/mTOR pathways and FOXO1. Regulates cardiac homeostasis and plays an important role in protection against cardiac hypertrophy. Acts as a transcriptional cofactor, represses transactivator activity of ISL1 and MYOCD. {ECO:0000250|UniProtKB:A0A096MK47, ECO:0000250|UniProtKB:Q5FW52}.;
Intolerance Scores
- RVIS EVS
- 0.24
- RVIS percentile EVS
- 69.51
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- N
- Indispensability score
- 0.114
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |